JP2014504866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504866A5 JP2014504866A5 JP2013547846A JP2013547846A JP2014504866A5 JP 2014504866 A5 JP2014504866 A5 JP 2014504866A5 JP 2013547846 A JP2013547846 A JP 2013547846A JP 2013547846 A JP2013547846 A JP 2013547846A JP 2014504866 A5 JP2014504866 A5 JP 2014504866A5
- Authority
- JP
- Japan
- Prior art keywords
- single variable
- variable domain
- immunoglobulin single
- polypeptide
- tgfbetarii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430235P | 2011-01-06 | 2011-01-06 | |
| US61/430,235 | 2011-01-06 | ||
| PCT/EP2012/050061 WO2012093125A1 (en) | 2011-01-06 | 2012-01-04 | Ligands that bind tgf-beta receptor ii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016205978A Division JP6453289B2 (ja) | 2011-01-06 | 2016-10-20 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504866A JP2014504866A (ja) | 2014-02-27 |
| JP2014504866A5 true JP2014504866A5 (enExample) | 2015-01-08 |
| JP6062375B2 JP6062375B2 (ja) | 2017-01-18 |
Family
ID=45444622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547846A Expired - Fee Related JP6062375B2 (ja) | 2011-01-06 | 2012-01-04 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
| JP2016205978A Expired - Fee Related JP6453289B2 (ja) | 2011-01-06 | 2016-10-20 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016205978A Expired - Fee Related JP6453289B2 (ja) | 2011-01-06 | 2016-10-20 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9150651B2 (enExample) |
| EP (1) | EP2661449B1 (enExample) |
| JP (2) | JP6062375B2 (enExample) |
| KR (1) | KR101886898B1 (enExample) |
| CN (1) | CN103443126B (enExample) |
| AU (1) | AU2016203609A1 (enExample) |
| BR (1) | BR112013016917A2 (enExample) |
| CA (1) | CA2823104A1 (enExample) |
| CL (1) | CL2013001975A1 (enExample) |
| CO (1) | CO6811807A2 (enExample) |
| CR (1) | CR20130376A (enExample) |
| DO (1) | DOP2013000162A (enExample) |
| EA (1) | EA201391012A1 (enExample) |
| ES (1) | ES2627299T3 (enExample) |
| IL (1) | IL227254A0 (enExample) |
| MA (1) | MA34820B1 (enExample) |
| MX (1) | MX2013007936A (enExample) |
| PE (1) | PE20140982A1 (enExample) |
| PH (1) | PH12013501397A1 (enExample) |
| SG (1) | SG191762A1 (enExample) |
| WO (1) | WO2012093125A1 (enExample) |
| ZA (1) | ZA201304726B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US9150651B2 (en) * | 2011-01-06 | 2015-10-06 | Glaxo Group Limited | Single variable domain immunoglobulins that bind TGF-beta receptor II |
| CA3141978A1 (en) * | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| MX374811B (es) * | 2013-03-15 | 2025-03-06 | Ac Immune Sa | Anticuerpos anti-tau y métodos de uso. |
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| CN120919282A (zh) | 2013-11-21 | 2025-11-11 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| CN113248613B (zh) * | 2014-01-15 | 2024-08-23 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN结合性质的Fc区变体 |
| CN106794233B (zh) | 2014-08-01 | 2021-11-12 | 布里格姆及妇女医院股份有限公司 | 与肺动脉高压的治疗有关的组合物和方法 |
| AU2016282334B2 (en) | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| WO2017041114A2 (en) * | 2015-09-03 | 2017-03-09 | The Children's Mercy Hospital | Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| MX2018003822A (es) | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. |
| HUE057241T2 (hu) * | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| RU2018138122A (ru) | 2016-04-05 | 2020-05-12 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Новая терапия |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| JP7542799B2 (ja) * | 2018-07-04 | 2024-09-02 | 京都府公立大学法人 | 眼組織の線維化抑制用組成物 |
| EP4003399A4 (en) * | 2019-07-26 | 2023-04-26 | Board Of Trustees Of Michigan State University | METHODS OF PREVENTING OR TREATMENT OF FATTY ACID DEGENERATION OF SKELETON MUSCLES |
| CN116199780A (zh) * | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| KR102314157B1 (ko) * | 2020-01-10 | 2021-10-19 | 주식회사 뉴클릭스바이오 | TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법 |
| WO2022099090A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | Heterodimeric antibodies that bind tgfbrii |
| WO2022172085A2 (en) | 2021-02-15 | 2022-08-18 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| CN116804062A (zh) * | 2022-03-23 | 2023-09-26 | 昆山新蕴达生物科技有限公司 | 一种FcRn结合纳米颗粒及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| JP2001206899A (ja) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| JP4889493B2 (ja) | 2003-05-14 | 2012-03-07 | ドマンティス リミテッド | ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法 |
| JP5087274B2 (ja) | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| ATE479760T1 (de) | 2004-03-24 | 2010-09-15 | Domantis Ltd | Universelles signalpeptid gas1 |
| GB0418651D0 (en) | 2004-08-20 | 2004-09-22 | Medical Res Council | Method |
| US20070012251A1 (en) | 2005-07-07 | 2007-01-18 | Martin Zucker | Seal arrangement with corrosion barrier and method |
| BRPI0710572A2 (pt) | 2006-01-24 | 2013-01-08 | Domantis Limited | ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| MX2012001278A (es) * | 2009-07-29 | 2012-03-16 | Glaxo Group Ltd | Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii. |
| CA2780221A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| US9150651B2 (en) * | 2011-01-06 | 2015-10-06 | Glaxo Group Limited | Single variable domain immunoglobulins that bind TGF-beta receptor II |
-
2012
- 2012-01-04 US US13/978,228 patent/US9150651B2/en not_active Expired - Fee Related
- 2012-01-04 EP EP12700019.8A patent/EP2661449B1/en active Active
- 2012-01-04 MX MX2013007936A patent/MX2013007936A/es not_active Application Discontinuation
- 2012-01-04 WO PCT/EP2012/050061 patent/WO2012093125A1/en not_active Ceased
- 2012-01-04 EA EA201391012A patent/EA201391012A1/ru unknown
- 2012-01-04 BR BR112013016917A patent/BR112013016917A2/pt not_active Application Discontinuation
- 2012-01-04 CA CA2823104A patent/CA2823104A1/en not_active Abandoned
- 2012-01-04 ES ES12700019.8T patent/ES2627299T3/es active Active
- 2012-01-04 JP JP2013547846A patent/JP6062375B2/ja not_active Expired - Fee Related
- 2012-01-04 CN CN201280012010.6A patent/CN103443126B/zh not_active Expired - Fee Related
- 2012-01-04 PE PE2013001516A patent/PE20140982A1/es not_active Application Discontinuation
- 2012-01-04 KR KR1020137020615A patent/KR101886898B1/ko not_active Expired - Fee Related
- 2012-01-04 PH PH1/2013/501397A patent/PH12013501397A1/en unknown
- 2012-01-04 SG SG2013049663A patent/SG191762A1/en unknown
- 2012-01-04 MA MA36101A patent/MA34820B1/fr unknown
-
2013
- 2013-06-25 ZA ZA2013/04726A patent/ZA201304726B/en unknown
- 2013-06-27 IL IL227254A patent/IL227254A0/en unknown
- 2013-07-03 DO DO2013000162A patent/DOP2013000162A/es unknown
- 2013-07-05 CL CL2013001975A patent/CL2013001975A1/es unknown
- 2013-07-16 CO CO13168686A patent/CO6811807A2/es unknown
- 2013-08-05 CR CR20130376A patent/CR20130376A/es unknown
-
2015
- 2015-09-02 US US14/843,250 patent/US9850307B2/en not_active Expired - Fee Related
-
2016
- 2016-05-31 AU AU2016203609A patent/AU2016203609A1/en not_active Abandoned
- 2016-10-20 JP JP2016205978A patent/JP6453289B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-21 US US15/818,861 patent/US20180086835A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211053T1 (hr) | Modificirani fgf-21 polipeptidi i njihove primjene | |
| PH12013501397A1 (en) | Ligands that bind tgf-beta receptor ii | |
| JP2014158480A5 (enExample) | ||
| JP2017537612A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2017081939A5 (enExample) | ||
| EP4317185A3 (en) | Fully-human post-translationally modified antibody therapeutics | |
| JP2016536361A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2017101068A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2012511545A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2013520996A5 (enExample) | ||
| NZ607394A (en) | Vegf-binding molecules | |
| JP2016502515A5 (enExample) | ||
| HRP20200936T1 (hr) | Antitijela za beta amiloid | |
| JP2011519571A5 (enExample) | ||
| RU2018147413A (ru) | PD-L1 специфические антитела | |
| JP2011506483A5 (enExample) | ||
| JP2015533795A5 (enExample) | ||
| AR078515A1 (es) | Moleculas de union biespecificas de union a vegf (factor de crecimiento endotelial vascular) y a dll4 (ligando 4 de tipo delta) para la terapia anti-angiogenesis | |
| PE20080112A1 (es) | Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas | |
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba |